1. Home
  2. CFND vs CELU Comparison

CFND vs CELU Comparison

Compare CFND & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$5.04

Market Cap

36.5M

Sector

N/A

ML Signal

N/A

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.60

Market Cap

50.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFND
CELU
Founded
N/A
2016
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.5M
50.7M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
CFND
CELU
Price
$5.04
$1.60
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
N/A
62.5K
Earning Date
N/A
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$40,578,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.00
52 Week High
N/A
$4.35

Technical Indicators

Market Signals
Indicator
CFND
CELU
Relative Strength Index (RSI) N/A 33.82
Support Level N/A $1.62
Resistance Level N/A $2.01
Average True Range (ATR) 0.00 0.13
MACD 0.00 -0.02
Stochastic Oscillator 0.00 2.82

Price Performance

Historical Comparison
CFND
CELU

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: